Complement activation in patients with primary antiphospholipid syndrome

Annals of the Rheumatic Diseases

Volumn 68, Issue 6, 2009, Pages 1030-1035

  Oku, K ^a   Atsumi, T ^a   Bohgaki, M ^a   Amengual, O ^a   Kataoka, H ^a   Horita, T ^a   Yasuda, S ^a   Koike, T ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPHYLATOXIN; COMPLEMENT; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C5A; COMPLEMENT FACTOR H; FIBRINOGEN; REGULATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTICOAGULATION; ANTIGEN ANTIBODY COMPLEX; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; HYPOCOMPLEMENTAEMIA; IMMUNE DEFICIENCY; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; ANTIGEN-ANTIBODY COMPLEX; ANTIPHOSPHOLIPID SYNDROME; BLOOD COAGULATION; CASE-CONTROL STUDIES; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT C3A; COMPLEMENT C4; COMPLEMENT C4A; CONNECTIVE TISSUE DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 67449159236     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.090670     Document Type: Article

References (41)

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
2. Atsumi T, Matsuura E, Koike T. Immunology of antiphospholipid antibodies and cofactors. In: Lahita RG, ed. Systemic lupus erythematosus. 4th ed. San Diego: Academic Press, 2004:1081-1105
3. Raschi E, Testoni C, Bosisio D, Borghi MO, Koike T, Mantovani A, et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003;101:3495-3500 (Pubitemid 36857933)
4. Bohgaki M, Atsumi T, Yamashita Y, Yasuda S, Sakai Y, Furusaki A, et al. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2 glycoprotein I antibodies. Int Immunol 2004;16:1633-1641 (Pubitemid 39480782)
5. Del Papa N, Sheng YH, Raschi E, Kandiah DA, Tincani A, Khamashta MA, et al. Human beta 2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for antibeta 2-glycoprotein I antibodies. J Immunol 1998;160:5572-5578 (Pubitemid 28267851)
6. Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GL, Harris EN. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999;99:1997-2002. (Pubitemid 29183897)
7. Amengual O, Atsumi T, Khamashta MA, Bertolaccini ML, Hughes GR. IgG2 restriction of anti-beta2-glycoprotein I as the basis for the association between IgG2 anticardiolipin antibodies and thrombosis in the antiphospholipid syndrome. Arthritis Rheum 1998;41:1513-1515
8. Zhou H, Wolberg AS, Roubey RA. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 2004;104:2353-2358 (Pubitemid 39331833)
9. Vega-Ostertag M, Harris EN, Pierangeli SS. Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum 2004;50:2911-2919 (Pubitemid 39209530)
10. Takeuchi R, Atsumi T, Ieko M, Amasaki Y, Ichikawa K, Koike T. Suppressed intrinsic fibrinolytic activity by monoclonal anti-beta-2 glycoprotein I autoantibodies: possible mechanism for thrombosis in patients with antiphospholipid syndrome. Br J Haematol 2002;119:781-788 (Pubitemid 35366224)
11. Atsumi T, Khamashta MA, Amengual O, Donohoe S, Mackie I, Ichikawa K, et al. Binding of anticardiolipin antibodies to protein C via beta2-glycoprotein I (beta2-GPI): a possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system. Clin Exp Immunol 1998;112:325-333 (Pubitemid 28266694)
12. Ieko M, Ichikawa K, Triplett DA, Matsuura E, Atsumi T, Sawada K, et al. Beta2- glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies. Arthritis Rheum 1999;42:167-174 (Pubitemid 29042583)
13. Forastiero RR, Martinuzzo ME, Lu L, Broze GJ. Autoimmune antiphospholipid antibodies impair the inhibition of activated factor X by protein Z/protein Z-dependent protease inhibitor. J Thromb Haemost 2003;1:1764-1770
14. Walport MJ. Complement. First of two parts. N Engl J Med 2001;344:1058-1066
15. Polley MJ, Nachman RL. Human platelet activation by C3a and C3a des-Arg. J Exp Med 1983;158:603-615
16. Chenoweth DE, Hugli TE. Human C5a and C5a analogs as probes of the neutrophil C5a receptor. Mol Immunol 1980;17:151-161 (Pubitemid 10164302)
17. Skokowa J, Ali SR, Felda O, Kumar V, Konrad S, Shushakova N, et al. Macrophages induce the inflammatory response in the pulmonary Arthus reaction through G alpha i2 activation that controls C5aR and Fc receptor cooperation. J Immunol 2005;174:3041-3050 (Pubitemid 40279725)
18. Girardi G, Berman J, Redecha P, Spruce L, Thurman JM, Kraus D, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003;112:1644-1654 (Pubitemid 38063722)
19. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004;10:1222-1226 (Pubitemid 39540439)
20. Salmon JE, Girardi G, Lockshin MD. The antiphospholipid syndrome as a disorder initiated by inflammation: implications for the therapy of pregnant patients. Nat Clin Pract Rheumatol 2007;3:140-147 (Pubitemid 46416262)
21. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42:1309-1311 (Pubitemid 30265586)
22. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
23. Pfeifer PH, Kawahara MS, Hugli TE. Possible mechanism for in vitro complement activation in blood and plasma samples: futhan/EDTA controls in vitro complement activation. Clin Chem 1999;45:1190-1199 (Pubitemid 29424257)
24. Harris EN, Gharavi AE, Patel BM, Hughes GRV. Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 1987;68:215-222
25. Amengual O, Atsumi T, Khamashta MA, Koike T, Hughes GR. Specificity of ELISA for antibody to beta 2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol 1996;35:1239-1243 (Pubitemid 27032941) (Pubitemid 126719666) (Pubitemid 126433805)
26. Atsumi T, Ieko M, Bertolaccini ML, Ichikawa K, Tsutsumi A, Matsuura E, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 2000;43:1982-1993 (Pubitemid 30953261)
27. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/ Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995;74:1185-1190
28. Chenoweth DE, Cooper SW, Hugli TE, Stewart RW, Blackstone EH, Kirklin JW. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med 1981;304:497-503. (Pubitemid 11056494)
29. Chenoweth DE, Cheung AK, Henderson LW. Anaphylatoxin formation during hemodialysis: effects of different dialyzer membranes. Kidney Int 1983;24:764-769 (Pubitemid 14160958)
30. Belmont HM, Hopkins P, Edelson HS, Kaplan HB, Ludewig R, Weissmann G, et al. Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease. Arthritis Rheum 1986;29:1085-1089
31. Richani K, Soto E, Romero R, Espinoza J, Chaiworapongsa T, Nien JK, et al. Normal pregnancy is characterized by systemic activation of the complement system. J Matern Fetal Neonatal Med 2005;17:239-245 (Pubitemid 40992323)
32. Ritis K, Doumas M, Mastellos D, Micheli A, Giaglis S, Magotti P, et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol 2006;177:4794-4802 (Pubitemid 44469814)
33. Arumugam TV, Magnus T, Woodruff TM, Proctor LM, Shiels IA, Taylor SM. Complement mediators in ischemia-reperfusion injury. Clin Chim Acta 2006;374:33-45. (Pubitemid 44572249)
34. Weeks C, Moratz C, Zacharia A, Stracener C, Egan R, Peckham R et al., Decayaccelerating factor attenuates remote ischemia-reperfusion-initiated organ damage. Clin Immunol 2007;124:311-327 (Pubitemid 47247607)
35. Peerschke EI,Yin W, Grigg SE, Ghebrehiwet B. Blood platelets activate the classical pathway of human complement. J Thromb Haemost 2006;4:2035-2042 (Pubitemid 44226786)
36. Matuura E, Kobayashi K, Koike T, Shoenfeld Y, Khamashta MA, Hughes GR. Atherogenic autoantigen: oxidized LDL complexes with beta2-glycoprotein I. Immunobiology 2003;207:17-22. (Pubitemid 36285091)
37. Loizou S, Cofiner C, Weetman AP, Walport MJ. Immunoglobulin class and IgG subclass distribution of antiphospholipid antibodies in patients with systemic lupus erythematosus and associated disorders. Clin Exp Immunol 1992;90:434-439 (Pubitemid 23001813)
38. Samarkos M, Davies KA, Gordon C, Walport MJ, Loizou S. IgG subclass distribution of antibodies against beta(2)-GP1 and cardiolipin in patients with systemic lupus erythematosus and primary antiphospholipid syndrome, and their clinical associations. Rheumatology (Oxford) 2001;40:1026-1032
39. Hammond A, Rudge AC, Loizou S, Bowcock SJ, Walport MJ. Reduced numbers of complement receptor type 1 on erythrocytes are associated with increased levels of anticardiolipin antibodies. Findings in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Arthritis Rheum 1989;32:259-264
40. Bertolaccini ML, Atsumi T, Lanchbury JS, Caliz AR, Katsumata K, Vaughan RW, et al. Plasma tumor necrosis factor alpha levels and the 2238*A promoter polymorphism in patients with antiphospholipid syndrome. Thromb Haemost 2001;85:198-203. (Pubitemid 32140560)
41. Berman J, Girardi G, Salmon JE. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 2005;174:485-490 (Pubitemid 40007438)